It was found that a significantproportion of patients showed immunity against at least one peptide.337 On the basis of these results, a phase 1 clinicaltrial using five FR-α peptides (with GM-CSF adjuvant) was launchedinvolving ovarian and breast cancer patients.338 The vaccine was reported to be well tolerated in all patientsand to elicit or augment immunity in more than 90% of patients. Here, FOLR1 is linked to breast carcinoma.